The study also elaborated that the GLUT1-mTORC1 axis is the main METTL3 target in CRC and targeting METTL3 and mTORC1 has a significant potential to inhibit CRC growth, suggesting that METTL3 could be used as a target to treat patients with CRC (69). The gene discussed is METTL3; the disease is colorectal carcinoma.